CATIONIC LIPID
    3.
    发明公开
    CATIONIC LIPID 审中-公开

    公开(公告)号:EP4289814A1

    公开(公告)日:2023-12-13

    申请号:EP22749755.9

    申请日:2022-02-02

    IPC分类号: C07C217/08

    摘要: The present invention provides novel cationic lipids having excellent encapsulation and delivery stability of nucleic acid medicines. Provided is a compound represented by Formula (I) or a pharmacologically acceptable salt thereof. In the Formula (I), R 1 is a substituted or unsubstituted formula: - (CH 2 ) a -L 1 -(CH 2 ) b -CH 3 ; R 2 is a substituted or unsubstituted C5-C20 alkyl group or a substituted or unsubstituted formula: -(CH 2 ) c -L 2 -(CH 2 ) d -CH 3 ; L 1 and L 2 are each independently -C(=O)O-, -OC(=O)-, or -OC(=O)O-; a, b, c, and d are each independently an integer of at least 1, and the total of a and b and the total of c and d are each an integer of 5 to 25; R 3 to R 7 are each independently a hydrogen atom, a substituted or unsubstituted C 1 -C 6 alkyl group, or the like; R 8 , R 9 , and R 10 are each a hydrogen atom; the constituent atoms in the Formula (I) may form a ring; Z is -OC(=O)-, -C(=O)O-, -OC(=O)O-, or the like; and X is O or S.

    POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVES FOR THE TREATMENT OF HIV

    公开(公告)号:EP4257137A2

    公开(公告)日:2023-10-11

    申请号:EP23192706.2

    申请日:2019-05-30

    IPC分类号: A61K31/55

    摘要: The present invention provides a compound represented by Formula (I):

    wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R 1 is halogen or the like; R 2a and R 2b are each independently hydrogen or the like; R 3 is substituted or unsubstituted alkyl or the like; R 4 is hydrogen or the like; and n is an integer of 1 to 3.

    DISSOLUTION TEST NET
    9.
    发明公开

    公开(公告)号:EP3954989A1

    公开(公告)日:2022-02-16

    申请号:EP20787320.9

    申请日:2020-04-07

    IPC分类号: G01N33/15

    摘要: When the mesh is placed under the bottom of a blade and over the bottom of a vessel in the dissolution test assembly equipped with either a vessel specified in the dissolution test method of the Japanese Pharmacopoeia, the United States Pharmacopoeia or the European Pharmacopoeia or a vessel used for the dissolution test, and a paddle formed from a blade and a shaft, and the suspensions and the solid dosage forms are added to or placed at the said mesh, a drug dissolves from the said dosage forms and the dissolution ratio variation between the said multiple same dosage forms can be small.